Masitinib Counteracts Resistance to Ovarian Cancer Therapy in Cell Cultures

Masitinib Counteracts Resistance to Ovarian Cancer Therapy in Cell Cultures
Researchers discovered how AB Science’s therapy masitinib — a veterinary medicine sold as Kinavet in the U.S. — acts to re-sensitize drug-resistant tumor cells to the anti-cancer treatment Gemzar (gemcitabine). The discovery could lead to better treatments for diseases where nucleoside analogues like Gemzar are used as therapy, such as in some viral diseases and

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

One comment

  1. Fitoussi says:

    Thank you so much for your accurate and impartial information

    This will give hope to all the patients. This is a true progress for science

    Eric

    Paris, France

Leave a Comment

Your email address will not be published. Required fields are marked *